Krystal Biotech (KRYS) Director Catherine Mazzacco Receives Awards

What Happened

• Catherine Mazzacco, a member of Krystal Biotech’s board of directors, received equity awards on Sept 14, 2026: 1,187 derivative awards (stock options) and 471 restricted stock units (RSUs). Both grants were reported at $0 in the Form 4 (typical for newly granted awards); vesting is scheduled in full on Sept 14, 2027 subject to continued board service and certain earlier vesting provisions.

Key Details

• Transaction date(s): Sept 14, 2026; Form 4 filed Sept 16, 2026 (timely filing).
• Reported amounts: 1,187 derivative awards (stock options) and 471 RSUs; reported price $0 (grant).
• Vesting: Options vest in full on Sept 14, 2027 (F1). Each RSU equals a contingent right to one share (F2); RSUs vest in full on Sept 14, 2027 (F3).
• Shares owned after transaction: Not provided in the excerpt of the filing.
• Filing timeliness: Reported within the normal Form 4 timeframe (no late filing indicated).

Context

• These are grants (compensation) to a non-employee director, a common practice for board compensation; they are not open-market purchases or sales and do not, by themselves, signal a buy/sell decision.
• The RSUs are rights to receive shares upon vesting; the options are derivative awards that will generally allow purchase of shares if and when exercised (subject to their terms). Vesting is contingent on continued service and certain acceleration events described in the company’s Non-Employee Director Compensation Policy.